ATE484281T1 - Heterocyclische verbindungen die als beta- lactamasehemmer aktiv sind - Google Patents

Heterocyclische verbindungen die als beta- lactamasehemmer aktiv sind

Info

Publication number
ATE484281T1
ATE484281T1 AT03709903T AT03709903T ATE484281T1 AT E484281 T1 ATE484281 T1 AT E484281T1 AT 03709903 T AT03709903 T AT 03709903T AT 03709903 T AT03709903 T AT 03709903T AT E484281 T1 ATE484281 T1 AT E484281T1
Authority
AT
Austria
Prior art keywords
beta
active
heterocyclic compounds
lactamase inhibitors
lactamase
Prior art date
Application number
AT03709903T
Other languages
German (de)
English (en)
Inventor
Jozsef Aszodi
Claude Fromentin
Maxime Lampilas
David Rowlands
Original Assignee
Novexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE484281(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novexel filed Critical Novexel
Application granted granted Critical
Publication of ATE484281T1 publication Critical patent/ATE484281T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03709903T 2002-01-28 2003-01-27 Heterocyclische verbindungen die als beta- lactamasehemmer aktiv sind ATE484281T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
PCT/FR2003/000243 WO2003063864A2 (fr) 2002-01-28 2003-01-27 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (1)

Publication Number Publication Date
ATE484281T1 true ATE484281T1 (de) 2010-10-15

Family

ID=27619669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03709903T ATE484281T1 (de) 2002-01-28 2003-01-27 Heterocyclische verbindungen die als beta- lactamasehemmer aktiv sind

Country Status (44)

Country Link
US (4) US7612087B2 (Sortimente)
EP (2) EP1480644B1 (Sortimente)
JP (1) JP4472346B2 (Sortimente)
KR (1) KR100979079B1 (Sortimente)
CN (3) CN101406471A (Sortimente)
AR (2) AR038234A1 (Sortimente)
AT (1) ATE484281T1 (Sortimente)
AU (1) AU2003214335B2 (Sortimente)
BE (1) BE2016C069I2 (Sortimente)
BR (1) BRPI0307267B8 (Sortimente)
CA (1) CA2474043C (Sortimente)
CL (1) CL2011000009A1 (Sortimente)
CO (1) CO5601014A2 (Sortimente)
CR (2) CR7387A (Sortimente)
CY (3) CY1111061T1 (Sortimente)
DE (1) DE60334527D1 (Sortimente)
DK (2) DK2279737T3 (Sortimente)
EA (1) EA007220B1 (Sortimente)
EC (1) ECSP045193A (Sortimente)
ES (2) ES2356813T3 (Sortimente)
FR (2) FR2835186B1 (Sortimente)
HR (1) HRP20040686B1 (Sortimente)
HU (1) HUS1600055I1 (Sortimente)
IL (1) IL163167A (Sortimente)
JO (1) JO2646B1 (Sortimente)
LT (1) LTC1480644I2 (Sortimente)
MA (1) MA26351A1 (Sortimente)
MX (1) MXPA04006621A (Sortimente)
MY (1) MY140638A (Sortimente)
NL (1) NL300847I2 (Sortimente)
NO (3) NO335195B1 (Sortimente)
NZ (1) NZ533936A (Sortimente)
OA (1) OA12761A (Sortimente)
PE (1) PE20030969A1 (Sortimente)
PL (1) PL220725B1 (Sortimente)
PT (2) PT1480644E (Sortimente)
RS (1) RS52137B (Sortimente)
SI (2) SI1480644T1 (Sortimente)
TN (1) TNSN04137A1 (Sortimente)
TW (1) TWI293071B (Sortimente)
UA (1) UA80271C2 (Sortimente)
UY (1) UY27626A1 (Sortimente)
WO (1) WO2003063864A2 (Sortimente)
ZA (1) ZA200405607B (Sortimente)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
DK2484680T3 (da) * 2005-12-07 2013-09-08 Basilea Pharmaceutica Ag Nyttige kombinationer af monolactam-antibiotika med beta-lactamase-inhibitorer
EP2040698A4 (en) * 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
JP2010507681A (ja) * 2006-10-23 2010-03-11 アイアールエム・リミテッド・ライアビリティ・カンパニー カテプシンプロテアーゼ阻害剤
US8563732B2 (en) * 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
ME02089B (me) * 2008-01-18 2014-04-30 Merck Sharp & Dohme Inhibitori beta-laktamaze
WO2009114921A1 (en) * 2008-03-17 2009-09-24 Dmitrienko Gary I INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2346820B1 (en) * 2008-06-11 2013-02-13 Shionogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
CN103180328B (zh) 2010-08-10 2016-10-26 莱姆派克斯制药公司 环硼酸酯衍生物及其治疗用途
EP2657234B1 (en) * 2010-12-22 2017-01-11 Meiji Seika Pharma Co., Ltd. Optically-active diazabicyclooctane derivative and method for manufacturing same
US8772490B2 (en) * 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
EP2721005B1 (en) * 2011-06-17 2015-11-25 AstraZeneca AB Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
EP2748165B1 (en) * 2011-08-27 2016-11-02 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
EP3052497B1 (en) * 2011-09-13 2017-06-28 Wockhardt Limited Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2013237869A1 (en) 2012-03-30 2014-10-23 Cubist Pharmaceuticals, Inc. Isoxazole beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8940897B2 (en) 2012-03-30 2015-01-27 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2874279C (en) * 2012-05-30 2021-03-16 Meiji Seika Pharma Co., Ltd. Diazabicyclooctane derivatives useful as .beta.-lactamase inhibitor and process for preparing the same
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112015003592B1 (pt) * 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
WO2014107535A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9132140B2 (en) 2013-01-04 2015-09-15 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
EP3050883B1 (en) 2013-09-24 2020-04-22 Meiji Seika Pharma Co., Ltd. Production method for diazabicyclooctane derivatives and intermediates
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
AU2014332960B2 (en) 2013-10-08 2018-03-29 Meiji Seika Pharma Co., Ltd. Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
KR20160115941A (ko) * 2014-02-20 2016-10-06 욱크하르트 리미티드 항세균제를 포함하는 제약학적 조합
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
HRP20191932T1 (hr) 2014-05-05 2020-01-24 Rempex Pharmaceuticals, Inc. Sinteza boronatnih soli i njihove uporabe
EP3145936B1 (en) 2014-05-19 2020-09-30 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
US10206937B2 (en) 2014-07-01 2019-02-19 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
PH12017500852B1 (en) * 2014-11-17 2023-03-08 Entasis Therapeutics Ltd Combination therapy for treatment of resistant bacterial infections
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016088863A1 (ja) 2014-12-05 2016-06-09 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の結晶及び安定な凍結乾燥製剤の製造法
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10183943B2 (en) * 2015-05-07 2019-01-22 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
JP2018515481A (ja) * 2015-09-16 2018-06-14 シュアンチュー ファーマ カンパニー，リミティド β−ラクタマーゼ阻害剤とその利用
US9951072B2 (en) 2015-10-02 2018-04-24 Legochem Biosciences, Inc. Compositions and methods for inhibiting beta-lactamase
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
ES2734773T3 (es) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Compuestos de dihidrooxadiazina para tratar infecciones y cáncer
CA3026582A1 (en) 2016-06-30 2018-01-04 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
PT3512851T (pt) 2016-09-16 2022-10-11 Entasis Therapeutics Ltd Compostos inibidores de beta-lactamase
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
RU2019124705A (ru) 2017-02-06 2021-02-05 Мутабилис Новые гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций
LT3630111T (lt) 2017-05-08 2022-03-10 Entasis Therapeutics, Inc. Junginiai ir būdai, skirti bakterinių infekcijų gydymui
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds
KR102626967B1 (ko) 2017-10-11 2024-01-18 큐펙스 바이오파마 인코포레이티드 보론산 유도체 및 이의 합성
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
PL3833665T3 (pl) 2018-08-09 2023-12-27 Antabio Sas Diazabicykloktanony jako inhibitory beta-laktamaz serynowych
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
EP4146650A4 (en) * 2020-09-01 2024-01-17 Ningxia Academy of Agriculture and Forestry Sciences BETA-LACTAMASE INHIBITORS AND THEIR PRODUCTION
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
US12410166B2 (en) 2021-05-07 2025-09-09 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
KR20240041506A (ko) 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
CN116375706B (zh) * 2023-02-22 2025-02-14 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
AU626427B2 (en) 1989-06-09 1992-07-30 Pharmacia & Upjohn Company Heterocyclic amines having central nervous system activity
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
EP1227103B1 (en) 1993-09-29 2006-07-26 Nabi Ring-expanded nucleosides and nucleotides
CN1046515C (zh) * 1993-12-29 1999-11-17 辉瑞大药厂 二氮杂双环神经激肽拮抗剂
EP0702004A2 (de) * 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
IL124912A0 (en) * 1996-01-03 1999-01-26 Smithkline Beecham Plc Carbamoyloxy derivatives of mutiline and their use as antibacterials
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
WO1999052875A1 (en) 1998-04-08 1999-10-21 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
AU4698399A (en) 1998-06-30 2000-01-17 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
SK7582001A3 (en) 1998-12-18 2002-03-05 Schering Corp Compound, method of therapy and pharmaceutical composition comprising the same, and its use for farnesyl protein transferase inhibition
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CA2386517A1 (en) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
US20030105118A1 (en) 2000-04-18 2003-06-05 Shuji Masumoto Tricyclic quinazolinediones
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
JP2004522781A (ja) 2001-02-22 2004-07-29 スクール オブ ファーマシー， ユニヴァーシティ オブ ロンドン 腫瘍処置のためのプロドラッグとしてのインドリンおよびテトラヒドロ−キノリン
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
BR0307267A (pt) 2004-12-07
CR20120356A (es) 2012-10-05
EP1480644A2 (fr) 2004-12-01
EP2279737A1 (fr) 2011-02-02
NO20043587L (no) 2004-08-27
OA12761A (fr) 2006-07-04
YU65804A (sh) 2006-08-17
MY140638A (en) 2010-01-15
CY1111061T1 (el) 2015-06-11
EP1480644B1 (fr) 2010-10-13
WO2003063864A2 (fr) 2003-08-07
FR2835186A1 (fr) 2003-08-01
CN1994301A (zh) 2007-07-11
CL2011000009A1 (es) 2011-03-25
KR100979079B1 (ko) 2010-08-31
HRP20040686A2 (en) 2004-12-31
CN101406471A (zh) 2009-04-15
EP2279737B1 (fr) 2012-10-31
NO335195B1 (no) 2014-10-20
LTPA2016037I1 (lt) 2017-01-10
BRPI0307267B8 (pt) 2021-05-25
DK2279737T3 (da) 2013-02-11
AU2003214335B2 (en) 2007-04-05
RS52137B (sr) 2012-08-31
NO2016024I1 (no) 2016-12-15
ECSP045193A (es) 2004-08-27
FR16C1019I2 (fr) 2017-12-29
AR100790A2 (es) 2016-11-02
DK1480644T3 (da) 2011-01-24
US20100048528A1 (en) 2010-02-25
SI2279737T1 (sl) 2013-07-31
BRPI0307267B1 (pt) 2016-02-10
CN1655781A (zh) 2005-08-17
HRP20040686B1 (hr) 2013-02-28
UY27626A1 (es) 2003-08-29
CN100482225C (zh) 2009-04-29
KR20040081473A (ko) 2004-09-21
US20050020572A1 (en) 2005-01-27
HUS1600055I1 (hu) 2017-01-30
FR2835186B1 (fr) 2006-10-20
CA2474043A1 (fr) 2003-08-07
PT1480644E (pt) 2011-01-17
PT2279737E (pt) 2013-02-01
TNSN04137A1 (fr) 2007-03-12
HK1077205A1 (zh) 2006-02-10
JP4472346B2 (ja) 2010-06-02
MA26351A1 (fr) 2004-10-01
WO2003063864A3 (fr) 2004-03-11
US20110245254A1 (en) 2011-10-06
FR16C1019I1 (fr) 2017-02-03
NO2016024I2 (no) 2016-12-15
EA007220B1 (ru) 2006-08-25
MXPA04006621A (es) 2004-10-04
BE2016C069I2 (Sortimente) 2022-05-17
SI1480644T1 (sl) 2011-03-31
LTC1480644I2 (lt) 2018-09-10
CY1114417T1 (el) 2016-08-31
NL300847I2 (Sortimente) 2017-01-03
CA2474043C (fr) 2011-08-02
CR7387A (es) 2010-10-25
JO2646B1 (en) 2012-06-17
CO5601014A2 (es) 2006-01-31
JP2005523897A (ja) 2005-08-11
NO2025027I1 (no) 2025-06-13
NZ533936A (en) 2007-05-31
TWI293071B (en) 2008-02-01
US20090215747A1 (en) 2009-08-27
US7612087B2 (en) 2009-11-03
CN100563653C (zh) 2009-12-02
HK1105864A1 (zh) 2008-02-29
ES2401855T3 (es) 2013-04-25
CY2016042I1 (el) 2017-03-15
AR038234A1 (es) 2005-01-05
EA200400981A1 (ru) 2005-02-24
IL163167A (en) 2010-04-15
PL371601A1 (pl) 2005-06-27
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
PL220725B1 (pl) 2015-12-31
ES2356813T3 (es) 2011-04-13
ZA200405607B (en) 2005-09-28
CY2016042I2 (el) 2017-03-15
DE60334527D1 (de) 2010-11-25
UA80271C2 (uk) 2007-09-10

Similar Documents

Publication Publication Date Title
ATE484281T1 (de) Heterocyclische verbindungen die als beta- lactamasehemmer aktiv sind
ATE401328T1 (de) Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren
ATE443706T1 (de) Pyrrolotriazinverbindungen als kinaseinhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DK1448523T3 (da) Heterocycliske forbindelser samt metoder til anvendelse deraf
DK1558585T3 (da) Neurologisk aktive forbindelser
ATE461191T1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
ATE404537T1 (de) Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE402934T1 (de) Malonamidderivate als gamma-secretaseinhibitoren
DE60320933D1 (de) Rho-kinase inhibitoren
DK1603570T3 (da) Aminoheteroarylforbindelser som proteinkinaseinhibitorer
DE602004028827D1 (de) Pyrrolodihydroisochinoline als pde10- inhibitoren
ATE411306T1 (de) Biarylsulfonamide als mmp-inhibitoren
ATE402700T1 (de) Glycinamid-derivate als raf-kinase-hemmer
ATE538787T1 (de) Benzimidazol-derivative als raf-kinase-hemmer
ATE461926T1 (de) Substituierte n-arylsulfonylheterocyclische amine als gamma-sekretase-hemmer
ATE425169T1 (de) Heterotricyclyl-6-alkylidenpeneme als beta- lactamaseinhibitoren
NO20052655D0 (no) Sammensmeltede heterocykliske forbindelser
EP1478356A4 (en) THERAPEUTIC COMPOUNDS
DE60328233D1 (de) Sulfamatbenzothiophenderivate als steroidsulfataseinhibitoren
ATE414063T1 (de) N-ä(ä4-substituierten piperazin-1- ylüsulfonylmethyl) alkylü -n-hydroxyformamide verbindungen als metalloproteinase inhibitoren
NL1026340A1 (nl) Beta-lactamaseremmerprodrug.
DE60335138D1 (de) Als pestizide geeignete verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1480644

Country of ref document: EP